Drugs in the Pipeline, News
Rilzabrutinib Fails in Phase 3 Pemphigus Trial
Rilzabrutinib is an oral Bruton tyrosine kinase inhibitor currently in development for a number of immune-mediated diseases.
Your search for oral corticosteroids returned 3 results
Drugs in the Pipeline
Oral JAK/SYK Inhibitor Granted Fast Track Designation for Atopic Dermatitis
The Food and Drug Administration (FDA) has granted Fast Track designation to the investigational oral dual inhibitor, ASN002 (Asana BioSciences), for the treatment of moderate-to-severe atopic dermatitis.
Drugs in the Pipeline
FDA to Review Promacta for First-Line Treatment of Severe Aplastic Anemia
The FDA decision to grant Priority Review was based on results from a National Institute of Health (NIH) study which demonstrated a 52% complete response rate and an 85% overall response rate in treatment-naïve SAA patients treated with eltrombopag plus standard IST.
